Bexmarilimab is under clinical development by Faron Pharmaceuticals and currently in Phase II for Myelodysplastic Syndrome. According to GlobalData, Phase II drugs for Myelodysplastic Syndrome have a 30% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how Bexmarilimab’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Bexmarilimab is under development for the treatment of hematological tumors including myelodysplastic syndrome, chronic myelomonocytic leukemia, relapsed and refractory acute myeloid leukemia, advanced or metastatic hepatocellular carcinoma, hepatobiliary system tumor, gallbladder cancer, intrahepatic or extrahepatic cholangiocarcinoma, colorectal cancer, anaplastic thyroid cancer, ovarian cancer, pancreatic ductal adenocarcinoma, metastatic uveal melanoma, gastric cancer including adenocarcinoma of the gastroesophageal junction, head and neck cancer squamous cell carcinoma, transitional cell cancer (urothelial cell cancer), metastatic breast cancer, cutaneous melanoma, head and neck cancer squamous cell carcinoma and urothelial cancer. The drug candidate is a humanized monoclonal IgG4 antibody targeting cells expressing CLEVER-1 (Common lymphatic endothelial and vascular endothelial receptor-1). It is administered intravenous and formulation in the form of solution. The drug candidate is based on the composite human antibody technology. The drug candidate is devoid of T cell epitopes which limits mounting of immune reaction against FP-1304.
It was under development for the treatment of renal cell cancer, colon cancer, TAM positive Hodgkin lymphoma, anti-CD20 resistant, lymphoma, tuberculosis, pertussis, glioblastoma, hematological tumor and opportunistic infections.
Faron Pharmaceuticals overview
Faron Pharmaceuticals (Faron) is a clinical stage biopharmaceutical company that develops novel treatments for medical conditions. The company’s clinical pipeline comprise of Traumakine, Bexmarilimab and Haematokine. Its Traumakine is an investigational intravenous (IV) interferon beta-1a therapy for the treatment of acute respiratory distress syndrome (ARDS) and other ischemic or hyperinflammatory conditions. The company’s Haematokine is an investigational Vascular Adhesion Protein 1 (VAP-1) inhibitor which blocks VAP-1 enzymatic activity to supports the expansion of human hematopoietic stem cells. Faron’s receptors involved in regulation of immune response in oncology, organ damage and bone marrow regeneration as a current pipeline. The company works in collaboration with academic institutions, pharmaceutical companies and contract research organizations for clinical development programmes. Faron is headquartered in Turku, Finland.
For a complete picture of Bexmarilimab’s drug-specific PTSR and LoA scores, buy the report here.